Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
GYGyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE)

NASDAQ Capital Market · Currency in USD
$6.07 ▲ +0.22 (+3.76%)
At close: Oct 26, 4:00 PM ET. Market closed.
$6.07 ▲ +0.00 (+0.00%)
After hours: Oct 26, 4:10 PM ET

Summary

Previous Close
$5.85
Open
$5.78
Day's Range
$5.78 – $6.10
52 Week Range
$5.44 – $9.14
Volume
93,373
Avg. Volume
113,719
Market Cap
$643.63M
Beta (5Y Monthly)
4.74
PE Ratio (TTM)
--
EPS (TTM)
-$0.17
Earnings Date
Nov 6, 2026
Forward Dividend & Yield
$0.96 (15.82%)
Ex-Dividend Date
Jan 13, 2023
1y Target Est
$17.00

Profile: Gyre Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
625
CEO
Ying Luo
Website
gyretx.com

Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease.

Earnings

Next report: Fri, Nov 6, 2026
EPS estimate -$0.15 · Revenue est. $28.40M
DateEst.Actual
Aug 7, 2026-$0.06-$0.12Miss
May 7, 2026-$0.06-$0.05Beat
Mar 12, 2026$0.06-$0.02Miss
Nov 7, 2025$0.05$0.06Beat
Aug 11, 2025$0.03$0.02Miss
May 9, 2025$0.03$0.03Beat

Analyst view

Consensus price target
$17.00 ▲ +180.1%
Range $16.00 – $18.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on GYRE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.